Haemonetics

Haemonetics

Verified
Provider of blood and plasma supplies and services. Learn more

Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
$4.9b (Public information from Jun 2024)
Boston Massachusetts (HQ)
Deals in current and previous year:

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
USD2020202120222023202420252026
Revenues0000000000000000000000000000
% growth2 %(12 %)14 %18 %11 %6 %6 %
EBITDA0000000000000000000000000000
% EBITDA margin27 %16 %17 %21 %28 %28 %27 %
Profit0000000000000000000000000000
% profit margin8 %9 %4 %10 %10 %12 %13 %
EV / revenue00.0x00.0x00.0x00.0x00.0x00.0x00.0x
EV / EBITDA00.0x00.0x00.0x00.0x00.0x00.0x00.0x
R&D budget0000000000000000000000000000
R&D % of revenue3 %4 %5 %4 %---

Source: Dealroom estimates

  • Edit
Get premium to view all results
DateInvestorsAmountRound
-investor

$0.0

round
N/A

$0.0

round
N/A

$0.0

round
N/A

$0.0

round
*
N/A

$600m

Post IPO Convertible
Total Funding000k

Recent News about Haemonetics

Edit
More about Haemoneticsinfo icon
Edit

Haemonetics Corporation is a leading provider of innovative medical technology solutions aimed at improving the quality, effectiveness, and efficiency of healthcare. The company primarily serves healthcare professionals and institutions, including hospitals and plasma donation centers. Haemonetics operates in the medical technology market, focusing on critical care settings where patient outcomes and economic efficiency are paramount.

The company's business model revolves around developing and selling advanced medical products and services. These include technologies that enhance plasma yield collections, boost productivity, and improve the donor experience in plasma centers. By offering these solutions, Haemonetics helps healthcare providers optimize their operations, leading to better patient care and improved economic outcomes.

Haemonetics generates revenue through the sale of its medical technology products and services. This includes both one-time sales of equipment and recurring revenue from service contracts and consumables used in their devices. The company is also committed to corporate responsibility, actively managing environmental, social, and governance risks and opportunities.

In summary, Haemonetics is dedicated to advancing patient care through innovative medical technologies, serving healthcare professionals and institutions in critical care settings, and maintaining a strong focus on corporate responsibility.

Keywords: medical technology, healthcare, plasma collection, patient care, productivity, donor experience, economic outcomes, innovation, corporate responsibility, critical care.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.

Investments by Haemonetics

Edit
Neoteric Technology
ACQUISITION by Haemonetics Apr 2009
Altivation Software
ACQUISITION by Haemonetics Apr 2009
Global Med Technologies
ACQUISITION by Haemonetics Apr 2010
Hemerus Medical
ACQUISITION by Haemonetics Apr 2012
Transfusion Technologies
ACQUISITION by Haemonetics Sep 2000
Attune Medical
ACQUISITION by Haemonetics Mar 2024
Medicell
ACQUISITION by Haemonetics Apr 2008
Opsens
ACQUISITION by Haemonetics Oct 2023